Enanta Pharmaceuticals (ENTA) Stock Rating Lowered by BidaskClub
Enanta Pharmaceuticals (NASDAQ:ENTA) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday.
ENTA has been the subject of several other research reports. TheStreet cut Enanta Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Monday, November 26th. Zacks Investment Research raised Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $87.00 price target for the company in a research note on Tuesday, October 9th. Oppenheimer set a $100.00 price target on Enanta Pharmaceuticals and gave the company a “hold” rating in a research note on Tuesday, August 14th. Finally, ValuEngine cut Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 8th. Six research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $104.00.
Shares of NASDAQ ENTA opened at $73.03 on Friday. The company has a market capitalization of $1.48 billion, a P/E ratio of 20.99 and a beta of 0.91. Enanta Pharmaceuticals has a 52 week low of $47.49 and a 52 week high of $127.77.
In related news, VP Nathalie Adda sold 4,155 shares of the business’s stock in a transaction that occurred on Thursday, September 20th. The stock was sold at an average price of $95.32, for a total value of $396,054.60. Following the completion of the sale, the vice president now directly owns 4,155 shares in the company, valued at approximately $396,054.60. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Tim Ocain sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $83.64, for a total value of $2,091,000.00. The disclosure for this sale can be found here. 10.56% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of ENTA. Principal Financial Group Inc. lifted its holdings in Enanta Pharmaceuticals by 3.2% in the 1st quarter. Principal Financial Group Inc. now owns 113,524 shares of the biotechnology company’s stock worth $9,185,000 after purchasing an additional 3,565 shares during the last quarter. TD Asset Management Inc. lifted its holdings in Enanta Pharmaceuticals by 203.2% in the 2nd quarter. TD Asset Management Inc. now owns 40,761 shares of the biotechnology company’s stock worth $4,724,000 after purchasing an additional 27,319 shares during the last quarter. First Trust Advisors LP acquired a new stake in Enanta Pharmaceuticals in the 2nd quarter worth approximately $8,029,000. Alps Advisors Inc. lifted its holdings in Enanta Pharmaceuticals by 6.0% in the 2nd quarter. Alps Advisors Inc. now owns 33,135 shares of the biotechnology company’s stock worth $3,840,000 after purchasing an additional 1,872 shares during the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in Enanta Pharmaceuticals in the 2nd quarter worth approximately $354,000. Hedge funds and other institutional investors own 85.18% of the company’s stock.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.
Featured Article: Stock Symbols and CUSIP Explained
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.